US-based Preventice Solutions is set to commercially introduce its BodyGuardian Heart remote patient monitoring system and PatientCare platform in the third quarter of this year.

The BodyGuardian system obtained 510(k) approval from the US Food and Drug Administration (FDA) in August 2012.

It is said to detect records and wirelessly transmit physiological data to support remote monitoring of non-lethal and cardiac arrhythmias in ambulatory patients.

Preventice president and chief global strategy officer Jon Otterstatter said: "We are close to achieving two important milestones for the BodyGuardian with the commercial availability in early summer and robust piloting here in the US.

"The beta testing is a direct indicator of significant interest in BodyGuardian by early adopters and proves their belief that Preventice Solutions is poised to change the future of remote monitoring."

According to the company, data will be transmitted to the monitoring center platform that can be stored up to 30 days and physicians can retrieve patient data and reports or choose to receive alerts based on changes in select biometrics.

The company will exhibit the BodyGuardian Heart and the PatientCare Platform at the HRS 2015 in Boston, which will be held from 13 to 16 May.